The perspective of mainstream says:
- Eli Lilly's Zepbound has become a blockbuster drug in the weight loss market, with sales of over $1.2 billion in the first quarter of 2024.
- The company's weight loss drug, tirzepatide, significantly reduced the risk of developing diabetes in patients with prediabetes and obesity, with patients 94% less likely to develop type 2 diabetes and losing an average 22.9% of their body weight.
- Eli Lilly's medicines Zepbound and Mounjaro are approved to treat obesity and type 2 diabetes, respectively, and the company is testing its uses in other conditions, including heart diseases, sleep apnea, and Alzheimer's disease.
- The total addressable market for obesity care medications could reach $100 billion by 2030.
- Eli Lilly's weight loss drug, tirzepatide, is expected to reach nearly $18 billion in sales this year, and the company is testing its uses in other conditions, including heart diseases, sleep apnea, and Alzheimer's disease.
- The company's ongoing research and development activities may lead to additional indications approved by regulators, expanding the addressable market and generating more revenue.
- Eli Lilly is expected to benefit from its successful tirzepatide franchise and potential regulatory approvals for new indications, making it a strong investment opportunity.
- The company's growth is driven by its weight loss and type 2 diabetes medicines, as well as potential new indications and research opportunities.
Layer3.news - mainstream perspective /
npub122…pprgp
2024-09-01 17:41:24
in reply to nevent1q…r8y8
Author Public Key
npub122cejpy9pnvcl7tr0dc9ar6pm75mrjr5gpgnll036zf060rw723qgpprgpPublished at
2024-09-01 17:41:24Event JSON
{
"id": "ac3bc9994362b2e0090044ff5481d13e92d2a9a91faf6284729de0585d917aa9",
"pubkey": "52b19904850cd98ff9637b705e8f41dfa9b1c87440513ffdf1d092fd3c6ef2a2",
"created_at": 1725212484,
"kind": 1,
"tags": [
[
"subject",
"The perspective of mainstream says:"
],
[
"p",
"52b19904850cd98ff9637b705e8f41dfa9b1c87440513ffdf1d092fd3c6ef2a2"
],
[
"e",
"0242284133e1f35f92fe97c7486dc4be85ad85d46afb3bacdb067eac3c045cf5",
"wss://articles.layer3.news",
"root"
]
],
"content": "The perspective of mainstream says:\n- Eli Lilly's Zepbound has become a blockbuster drug in the weight loss market, with sales of over $1.2 billion in the first quarter of 2024.\n- The company's weight loss drug, tirzepatide, significantly reduced the risk of developing diabetes in patients with prediabetes and obesity, with patients 94% less likely to develop type 2 diabetes and losing an average 22.9% of their body weight.\n- Eli Lilly's medicines Zepbound and Mounjaro are approved to treat obesity and type 2 diabetes, respectively, and the company is testing its uses in other conditions, including heart diseases, sleep apnea, and Alzheimer's disease.\n- The total addressable market for obesity care medications could reach $100 billion by 2030.\n- Eli Lilly's weight loss drug, tirzepatide, is expected to reach nearly $18 billion in sales this year, and the company is testing its uses in other conditions, including heart diseases, sleep apnea, and Alzheimer's disease.\n- The company's ongoing research and development activities may lead to additional indications approved by regulators, expanding the addressable market and generating more revenue.\n- Eli Lilly is expected to benefit from its successful tirzepatide franchise and potential regulatory approvals for new indications, making it a strong investment opportunity.\n- The company's growth is driven by its weight loss and type 2 diabetes medicines, as well as potential new indications and research opportunities.\n",
"sig": "d5b741b495f9915039998d9044bbde06a924f088b606c22b17c923f4050876c03e517c2fd843986349f3605d6b21a430464e133acbec60b227eb37b0badcaa1c"
}